Somatic cancer genetics in the UK : real-world data from phase I of the Cancer Research UK Stratified Medicine Programme
MetadataShow full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Introduction: Phase I of the Cancer Research UK Stratified Medicine Programme (SMP1) was designed to roll out molecular pathology testing nationwide at the point of cancer diagnosis, as well as facilitate an infrastructure where surplus cancer tissue could be used for research. It offered a non-trial setting to examine common UK cancer genetics in a real-world context. Methods: A total of 26 sites in England, Wales and Scotland, recruited samples from 7814 patients for genetic examination between 2011 and 2013. Tumour types involved were breast, colorectal, lung, prostate, ovarian cancer and malignant melanoma. Centralised molecular testing of surplus material from resections or biopsies of primary/metastatic tissue was performed, with samples examined for 3-5 genetic alterations deemed to be of key interest in site-specific cancers by the National Cancer Research Institute Clinical Study groups. Results: 10 754 patients (98% of those approached) consented to participate, from which 7814 tumour samples were genetically analysed. In total, 53% had at least one genetic aberration detected. From 1885 patients with lung cancer, KRAS mutation was noted to be highly prevalent in adenocarcinoma (37%). In breast cancer (1873 patients), there was a striking contrast in TP53 mutation incidence between patients with ductal cancer (27.3%) and lobular cancer (3.4%). Vast inter-tumour heterogeneity of colorectal cancer (1550 patients) was observed, including myriad double and triple combinations of genetic aberrations. Significant losses of important clinical information included smoking status in lung cancer and loss of distinction between low-grade and high-grade serous ovarian cancers. Conclusion: Nationwide molecular pathology testing in a non-trial setting is feasible. The experience with SMP1 has been used to inform ongoing CRUK flagship programmes such as the CRUK National Lung MATRIX trial and TRACERx.
Lindsay , C R , Shaw , E C , Blackhall , F , Blyth , K G , Brenton , J D , Chaturvedi , A , Clarke , N , Dick , C , Evans , T R J , Hall , G , Hanby , A M , Harrison , D J , Johnston , S R D , Mason , M D , Morton , D , Newton-Bishop , J , Nicholson , A G , Oien , K A , Popat , S , Rassl , D , Sharpe , R , Taniere , P , Walker , I , Wallace , W A , West , N P , Butler , R , Gonzalez de Castro , D , Griffiths , M & Johnson , P W M 2018 , ' Somatic cancer genetics in the UK : real-world data from phase I of the Cancer Research UK Stratified Medicine Programme ' , ESMO Open , vol. 3 , no. 6 , e000408 . https://doi.org/10.1136/esmoopen-2018-000408
Copyright © Author(s) 2018. Open Access article. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
DescriptionThis study was supported by Cancer Research UK, AstraZeneca and Pfizer UK.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.